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Background: Conventional luteal support packages are inadequate to facilitate a fresh transfer after GnRH agonist
(GnRHa) trigger in patients at high risk of developing ovarian hyperstimulation syndrome (OHSS). By providing
intensive luteal-phase support with oestradiol and progesterone satisfactory implantation rates can be sustained.
The objective of this study was to assess the live-birth rate and incidence of OHSS after GnRHa trigger and intensive
luteal steroid support compared to traditional hCG trigger and conventional luteal support in OHSS high risk Asian
patients.
Methods: We conducted a retrospective cohort study of 363 women exposed to GnRHa triggering with intensive
luteal support compared with 257 women exposed to conventional hCG triggering. Women at risk of OHSS were
defined by ovarian response ≥15 follicles ≥12 mm on the day of the trigger.
Results: Live-birth rates were similar in both groups GnRHa vs hCG; 29.8% vs 29.2% (p = 0.69). One late onset severe
OHSS case was observed in the GnRHa trigger group (0.3%) compared to 18 cases (7%) after hCG trigger.
Conclusions: GnRHa trigger combined with intensive luteal steroid support in this group of OHSS high risk Asian
patients can facilitate fresh embryo transfer, however, in contrast to previous reports the occurrence of late onset
OHSS was not completely eliminated.
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Gonadotrophin releasing hormone agonists (GnRHa) are
highly effective in inducing an LH surge, with levels
comparable to those observed during the spontaneous
surge during normal menstrual cycles [1]. These charac-
teristics have been exploited clinically, with avoidance of
hCG trigger and adoption of GnRHa trigger in women at
risk of ovarian hyperstimulation syndrome (OHSS) [2].
However, although a GnRHa induced LH surge is capable
of inducing oocyte maturation, it is significantly shorter
than that observed during natural cycle, leading to a* Correspondence: stamatina.iliodromiti@glasgow.ac.uk
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article, unless otherwise stated.compromised corpus luteal function [1,3]. Evidence for
defective luteal function included the observation that
GnRHa cycles have a shorter luteal phase and that the
luteal steroid profile is reduced in both non-supplemented
and supplemented in-vitro fertilisation (IVF) cycles, as
compared to an hCG trigger [4]. The clinical impact of
this defective corpus luteal function after a GnRHa
trigger, is that when combined with standard luteal
phase support, pregnancy rates are lower and miscarriage
rates higher [5-7].
Recognition of these issues has prompted debate regard-
ing the best strategy of luteal phase support to facilitate
fresh embryo transfer in GnRHa triggered cycles. Two
primary alternatives strategies have been suggested,
with both dissociating the ovulation trigger from the lutealtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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with a low dose of hCG administered after oocyte aspir-
ation to replace the actions of early luteal LH to sustain
implantation and endogenous luteal ovarian steroidogene-
sis [8-11]. The second avoids hCG and instead focuses on
correcting the abnormal luteal steroid profile by providing
intensive luteal-phase support with oestradiol and proges-
terone, only [12,13].
With respect to this second strategy Babayof et al. initially
reported the use of intensive oestradiol and progesterone
for luteal support in high-risk OHSS patients post GnRHa
trigger [12]. In that pilot study (N = 15 in GnRHa group,
N = 13 in hCG group) the luteal phase was supported by
50 mg/day of intramuscular progesterone, starting 36 h
after oocyte retrieval and if serum progesterone concen-
tration was below 40 nmol/l, the progesterone dose was
doubled. In addition if the serum oestradiol concentration
was below 200 pmol/l, oral oestrogen 4 mg/day was added.
Only one woman in the GnRHa trigger group achieved a
live birth (6.7%), as compared to two live births in the hCG
group where 11 women received an embryo transfer (18%).
Given these poor outcomes, Engmann et al. suggested a
more aggressive luteal support in their RCT in which 30
women in the GnRHa trigger group were treated with
50 mg/day of intramuscular progesterone, but aimed to
maintain levels above 20 ng/ml (63.6 nmol/l), while
oestrogen was added by 0.3 mg transdermal patches
every other day, and supplemented by a further 0.1 mg
and/or oral micronized oestradiol 2 mg twice a day
to maintain serum oestradiol levels above 200 pg/ml
(734 pmol/l) [13]. This approach was associated with sub-
stantially better ongoing pregnancy rates (53.3%), equiva-
lent to those observed in the hCG triggered control group
(48.3%). Importantly no OHSS case was reported after
GnRHa trigger versus 31% after hCG trigger. Shapiro and
colleagues subsequently reported their experience of a
similar enhanced luteal support strategy in 24 women
aiming to maintain serum oestradiol levels above 200 pg/ml
and progesterone above 15 ng/ml (47.7 pmol/l) and
reported a 50% ongoing pregnancy rate [14]. Imbar et al.
in their study of 70 women used a strategy of just 50 mg/
day of intramuscular progesterone plus 6 mg of oestradiol,
reported an overall live birth of 27.1% [15]. Lastly, Orvieto
reported in 67 women that use of either 100 mg intramus-
cular progesterone or 200 mg twice a day vaginal progester-
one combined with 6 mg oral micronized 17-β-oestradiol
was associated with a low clinical pregnancy rate of 14.9%
[16], comparable to pregnancy rates previously published
after GnRHa trigger without intensive luteal support
(Orvieto et al., 2006). No OHSS case was seen after
GnRHa trigger and intensive luteal support in any of the
above-mentioned trials.
Whether the wide variability in clinical outcomes after
GnRHa trigger and luteal steroid support, only, reflects thediffering steroid regimens or whether ethnical differences
may also play a role is unknown. However, it has been
suggested that follicular response and the associated peak
oestradiol at the time of GnRHa trigger may influence
treatment outcomes [17]. Specifically a peak oestradiol
of <4,000 pg/ml was associated with a lower ongoing
pregnancy rate, as compared to oestradiol >4,000 pg/ml
(ongoing pregnancy rate 33.2% vs 44.9%; p = 0.02) [17].
However, classically an excessive ovarian response has
been associated with a lower live birth rate [18] and in
this aspect supra-physiological oestradiol levels have been
shown to have a deleterious effect on embryo adhesion
and a direct toxic effect on the embryo [19].
Given the lack of consistency in the literature regarding
intensive luteal phase support with steroids, only, after
GnRHa trigger, we here report treatment outcomes in a
Vietnamese population after GnRHa trigger as compared
to controls exposed to an hCG trigger and conventional
luteal support.
Methods
Study subjects
This retrospective analysis summarizes the experience
from a large Vietnamese fertility centre using a GnRHa
protocol to trigger final oocyte maturation and an intensive
luteal support package and compares it with the use of
the conventional hCG trigger protocol, to facilitate a
fresh transfer in women deemed at high risk of developing
OHSS. All the patients undergoing the GnRHa trigger
protocol attended the clinic from January 2010 to October
2012. The criteria used for identifying women with a high
risk of developing OHSS included actual ovarian response
[20]; specifically ≥15 follicles measuring ≥12 mm in size
on the day of the trigger. The unexposed group included
all the patients fulfilling the same response criteria during
the same period receiving conventional hCG trigger. From
January 2012 to October 2012, the GnRHa package had
fully replaced the conventional hCG protocol for patients
deemed at high risk of OHSS, therefore there were no
patients with excessive ovarian response who received
the hCG conventional trigger protocol during this period.
The allocation of the patients to either protocol during
the transitional period was based on clinicians’ preference.
All cycles which used alternative techniques such as
‘coasting’, or cabergoline therapy to minimize the risk
of OHSS were excluded from the study. Figure 1 shows
a flowchart of the selection of the patients to each
protocol per year of treatment. Oocyte donation cycles
were also excluded. The clinical and laboratory personnel
did not change over the study period.
IVF treatment protocol
A GnRH antagonist protocol was used as the primary
mode of stimulation co-treatment with the gonadotrophin
High risk of OHSS ( 
follicles of >12mm)
N=748
HCG trigger, N=257
GnRH Agonist trigger, 
N=363
Coasting, N=2
Cabergoline, N=6
Albumin transfusion on 
day of OPU, N=2
IVM rescue, N=118
15
Figure 1 Flow chart depicting the various protocols used for
OHSS high risk patients in the unit during the study period
from January 2010 to October 2012. (OPU: ovum pick up, IVM:
in vitro maturation).
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The standard starting dose of recombinant follicle stimu-
lating hormone (rFSH, Puregon MSD) was 150 IU per day
for women under 36 years of age. Gonadotrophin doses
were, however, modified based on age, body mass index
(BMI), presence of polycystic ovary syndrome (PCOS),
antral follicle count (AFC), anti-müllerian hormone (AMH)
and previous history of OHSS so that starting FSH doses
ranged from 100 IU to 225 IU. Stimulation started on day 2
or 3 of the cycle and a GnRH antagonist was added on
day 5 of stimulation (day 6 of the cycle). Pelvic ultrasound
was performed on stimulation day 6, with adjustment of
the gonadotrophin according to ovarian response. Routine
ultrasound and endocrine monitoring were initiated
thereafter, with triggering when three follicles were ≥17 mm
in size. The decision to use a GnRHa trigger was made
in women with excessive follicular response (≥15 folli-
cles ≥12 mm). GnRHa was administered at least 8 hours
following the last GnRH antagonist injection. No upper
cut-off limit was used, with all women proceeding to trig-
ger in the GnRHa group. For the GnRHa trigger a sub-
cutaneous injection of 0.2 mg Triptorelin (Ipsen Beaufour,France) was used. Oocyte retrieval was performed 34 to
36 hours following GnRHa administration. Fertilization
was undertaken using standard protocols and all embryos
were cultured for two days, before being either transferred
or cryopreserved. Three embryos were routinely transferred
on day two of culture.
The luteal support strategy utilised was intramuscular
progesterone 50 mg once per day (Progesterone BP
25 mg, Rotexmedica, Germany) plus vaginal progesterone
twice daily (Crinone 90 mg, Merck Serono), and oestradiol
valerate 6 mg daily (Progynova 2 mg, Bayer Schering) ad-
ministered from the day of egg retrieval until menstruation
or 7 weeks of gestation. No additional monitoring for
adjustment of the steroidal dosage was performed.
In the hCG control group, stimulation was achieved
similarly with rFSH from day 2 to 3 combined with a
GnRH antagonist added on day 5 of stimulation. On
achieving 3 follicles ≥17 mm in size, 250 μg rhCG
(Ovitrelle, Merck Serono) was administered subcutane-
ously to induce oocyte maturation and egg retrieval
followed 34–36 hours later. Three embryos were trans-
ferred two days after routine embryo culture. Luteal sup-
port commenced on the day of egg retrieval consisting
of twice daily vaginal progesterone (Crinone 8%, Merck
Serono) until the day of the pregnancy test (14 days post
embryo transfer).
Ethics approval
Full ethics committee approval was not required due to
the retrospective nature of the study and the anonymised
handling of data.
Outcomes and statistical analysis
The two primary outcomes of this retrospective cohort
study were the live birth rate and the incidence of severe
OHSS. The Royal College of Obstetricians and Gynaecolo-
gist (RCOG) classification of OHSS was used with severe
OHSS requiring hospitalisation, and mild or moderate
OHSS managed on an outpatient basis [21]. Ongoing
pregnancy rate was defined as continuing pregnancy after
24 weeks. Positive pregnancy test was defined as a positive
serum hCG on day 16 post oocyte retrieval. Clinical preg-
nancy was defined by the presence of at least one fetal
heart on an 8 week ultrasound. Miscarriage was defined as
pregnancy loss before 24 weeks gestation. The implant-
ation rate was calculated by dividing the number of fetal
hearts detected at 8 weeks’ gestation ultrasound by the
number of embryos transferred. Multiple pregnancy rate
was defined as the proportion of multiple pregnancies at 8
weeks’ gestation scan divided by the number of clinical
pregnancies at this gestation. Live birth, positive pregnancy
test, clinical, ongoing pregnancy and miscarriage rates
are reported per cycle started unless otherwise stated. The
effect of peak oestradiol (E2) and LH on the pregnancy
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was also evaluated.
Statistical analysis was performed using Stata/SE
(version 12.1, Stata Corp, USA) and data are presented
as mean ± SD (standard deviation) when they have a
Gaussian distribution or median (25th-75th range) when
they are not normally distributed. Non parametric test
(Mann Whitney U) was used for not normally distributed
numerical variables and chi-squared or Fisher’s exact test
for categorical variables. Logistic regression was performed
with adjustment for confounders. P < 0.05 was considered
statistically significant for all analyses.
Results
Demographic data and cancellations
Table 1 shows the baseline patients characteristics of the
patients undergoing either GnRHa trigger followed by
the intense luteal support package or the traditional hCG
trigger protocol. Patients were in general young, slim
and had high ovarian reserve indices consistent with
an increased risk of an excessive ovarian response and
development of OHSS. Furthermore 8.3% of the patients
in the GnRHa group had previously experienced severe
OHSS compared with 1.6% in the control group. In the
GnRHa group 11.2% of the cycles (41 cycles out of 363)
were cancelled due to thin endometrium < 6 mm (n = 28),
personal reasons (n = 11) or early signs of OHSS (n = 2)
such as bloating and epigastric pain. In the hCG group
17% of the cycles (44 cycles out of 257) were cancelledTable 1 Baseline characteristics of the patients receiving
either GnRHa trigger accompanied with intensive luteal
steroid support or conventional hCG trigger for final
follicular maturation
GnRHa trigger plus
intensive luteal
steroid support
Conventional
hCG trigger
p
Cycles (n) 363 257
Age (years) 31 (28–34) 30 (28–34) 0.97
BMI (kg/m2) 20.4 (19.1-21.9) 20.3 (19.2-21.4) 0.59
History of OHSS (n,%) 30 (8.3%) 4 (1.6%) <0.0001
AMH (ng/ml) 5.85 (4–8.2) 6.17 (4.1-9.2) 0.36
AFC 16 (12–24) 13 (10–17) 0.0001
Aetiology (n,%)
Male 153 (42.1%) 153 (59.5%)
PCOS 102 (28.1%) 45 (17.5%)
Endometriosis 4 (1.1%) 5 (2%)
Tubal disease 62 (17.1%) 50 (19.5%)
Idiopathic 30 (8.3%) 4 (1.5%)
Unclassified 12 (3.3%)
Variables that are not normally distributed are expressed as median
(25th-75th percentile).due to either thin endometrium < 6 mm (n = 15), personal
reasons (n = 7) or early signs of developing OHSS (n = 22).Oocytes, embryos and reproductive outcome
Table 2 shows the treatment outcomes. A large number of
oocytes were collected with both protocols with appropriate
rates of fertilization, development and embryos available for
cryopreservation. The positive pregnancy rate was 36.9%
per cycle, with an overall clinical pregnancy rate of 30% per
cycle started and live-birth rate of 29.8% among the patients
that underwent the GnRHa trigger, which were similar
to those observed in the hCG group. All patients with
an ongoing pregnancy after 24 weeks had a live-birth in
the GnRHa group excluding one patient who moved
abroad and for whom information on delivery status
was not available. When the analysis was restricted to
women who had an embryo transfer, there was still no dif-
ference in live-birth rate between the two groups (p = 0.8).
The overall miscarriage rate was lower in the GnRHa
group compared to the hCG group per cycle started and
per embryo transfer. After adjustment for age, BMI and
cause of infertility the risk of miscarriage was still reduced
in the GnRHa group per cycle started (OR 0.41, 95% CI
0.23, 0.71) or if limited to those who had an embryo trans-
fer (OR 0.38, 95% CI 0.22, 0.67).Endocrinology
The peak oestradiol (E2) was recorded for 348 cycles
undergoing GnRH trigger for oocyte maturation. The
median peak serum E2 level was 11,850 pg/ml (8,700-
15,395 pg/ml). 27 patients (7.8%) had peak E2 < 4,000 pg/
ml and 321 patients (92.2%) peak E2 ≥ 4,000 pg/ml. The
median peak E2 among those having E2 < 4,000 pg/ml was
2,408 (1,751-3,070) and in those having E2 ≥ 4,000 pg/ml
was 12,350 (9,361-16,000) pg/ml. The ongoing pregnancy
rate in women having had E2 < 4,000 pg/ml was 48.2%
(13/27), whereas in patients with E2 ≥ 4,000 pg/ml was
28.4%% (91/321) per cycle started (p = 0.03). This difference
was maintained when the analysis was restricted to those
with an embryo transfer (p = 0.04). However, the distribu-
tion of peak E2 among those that became pregnant did
not differ from those that did not (p = 0.21). Similarly, in
univariate regression analysis pre-trigger E2 levels were
not associated with the chance of live-birth in women
undergoing GnRHa trigger (OR = 0.99, 95% CI 0.99-1,
p = 0.082). LH on the day of the trigger was measured in
257 women undergoing GnRH trigger for oocyte matur-
ation. The median LH level was 1.95 IU/L (1.21-3.48 IU/L).
Univariate regression analysis indicated that one unit higher
LH on the day of the GnRHa trigger increased the odds for
a live-birth by around 12% (OR= 1.12, 95% CI 1.002-1.25,
p = 0.046). Among those women with high (E2 ≥
4,000 pg/ml) and low peak E2 (E2 < 4,000 pg/ml), LH did
Table 2 Reproductive outcomes of patients exposed to GnRHa trigger and intensive luteal steroid support versus
patients exposed to conventional hCG trigger for final follicular maturation
GnRHa trigger plus intensive
luteal steroid support (N = 363)
Conventional hCG
trigger (N = 257)
p
Total FSH (IU) 1,500 (1,300-1,800) 1,650 (1,200-2,200) 0.12
Peak Oestradiol (E2) (pg/ml) 11,850 (8,700-15,395) 8,598 (5,510-12,350) 0.0001
LH on day of trigger (IU) 1.95 (1.21-3.48) 2.14 (1.28-3.49) 0.46
Follicles >12 mm 20 (17–25) 18 (16–21) 0.0001
Oocytes 19 (15–24) 18 (15–22) 0.02
Embryos 11 (7–15) 10 (7–13) 0.14
Embryo transfers (ET) (n,% of total cycles) 322 (88.7%) 213 (83%) 0.038
Cancellations of ET due to early signs of OHSS (n,% of total cycles) 2 (0.55%) 22 (8.6%) <0.0001
Embryos transferred 3 3
Positive pregnancy test (n,%per cycle) 134 (36.9%) 112 (43.5%) 0.095
Clinical Pregnancy (n,%per cycle) 109 (30%) 77 (30%) 0.99
Implantation rate (n,%) 137/966 (14.2%) 106/639 (16.6%) 0.978
Miscarriages (n,% per cycle) 5 (1.4%) 15 (5.8%) 0.002
Live birth rate (n,% per cycle) 108 (29.8%) 75 (29.2%) 0.69
Multiple pregnancy rate (n,% of live-birth) 28 (25.9%) 29 (38.7%) 0.067
OHSS cases (severe) (n,% per cycle) 1 (0.3%) 18 (7%) <0.0001
Variables that are not normally distributed are expressed as median (25th-75th percentile).
Outcome data are presented per cycle started unless otherwise stated.
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(0.97-2.9), p = 0.7).
OHSS
With respect to OHSS, there was one severe late OHSS
case (0.3%) among the women that had GnRHa trigger
for oocyte maturation as opposed to 18 cases (7%) among
the women having received the traditional hCG trigger
(p < 0.0001). After adjustment for age, BMI, peak oestradiol
and follicle number the odds ratio for development of
OHSS with GnRHa trigger was OR 0.02 (95%CI 0.003 -
0.18).
The single late onset OHSS case, which is the first case
reported in the literature after GnRHa trigger and intensive
luteal steroid support, only, occurred in a 30 year old
patient with a BMI of 20.4 kg/m2 who sought fertility
treatment for primary infertility due to a male factor. She
had a high baseline serum AMH of 10.68 ng/ml and an
AFC of 24. Stimulation was initialized on day 2 of her
cycle with 100 IU of recombinant FSH due to the high
ovarian reserve indices. On day 6 of the cycle, 0.25 mg of
a GnRH antagonist (Orgalutran, MSD) was added. On day
8, a pelvic ultrasound showed that there was only one
follicle > 17 mm in each ovary so stimulation continued
and a pelvic ultrasound was repeated on day 10 showing
an excessive follicular response (27 follicles >12 mm).
The pre-trigger peak E2 was 18,959 pg/ml; 32 oocytes
were collected and 24 embryos were cultured. After 2
days, three embryos were transferred as per the routineprotocol of the clinic. Ten days following the embryo
transfer, the patient started complaining of shortness of
breath and the following day she was admitted to the
hospital with severe epigastric pain, abdominal distension,
dyspnoea, mild ascites, minimal pleural effusion, a positive
pregnancy test and haematocrit of 45.3% (31.4% initially).
Initial management included supportive care, strict fluid
monitoring and thromboprophylaxis, however, while in
hospital, the ascites and pleural effusion deteriorated,
the abdominal circumference increased and the ovarian
volumes also increased. Intravenous albumin was adminis-
tered and paracentesis performed with initial drainage of
500 mls. An abdominal drain was left in situ with a further
300 mls of clear ascetic fluid drained over the next four
days, with removal of the drain thereafter. She continued
to improve clinically with supportive management and
was discharged after ten days. An ongoing twin pregnancy
was confirmed at scan which resulted in a delivery of two
healthy babies at 38 weeks of gestation. Interestingly, there
were two more cases in the GnRHa trigger group with early
signs of OHSS (bloating), however the embryo transfer
was cancelled and the patients did not require any further
treatment or hospitalisation.
Discussion
The application of GnRHa trigger in GnRH antagonist
controlled cycles has provided a unique opportunity to
minimize the risk of OHSS in controlled ovarian stimula-
tion. However, recognition of the poor clinical outcomes
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tologous fresh cycles has prevented its routine adoption
[22,23]. To overcome this deficiency a variety of intensive
luteal steroid support strategies have been assessed, with
variable results [13-15]. Herein we report that intensive
luteal support with exogenous steroids in a Vietnamese
population is capable of achieving live-birth rates compar-
able to those of a control group exposed to a conventional
hCG trigger. However, in contrast to previous reports,
GnRHa trigger with intensive luteal steroid support,
only, does not completely eliminate OHSS as one patient
developed late onset severe OHSS.
This is, to our knowledge, the largest retrospective
cohort study that evaluates the live-birth rates after
GnRHa trigger and intensive luteal steroid support,
only. A previous study which reported promising clinical
pregnancy outcomes with GnRHa trigger was debated due
to the majority of the participants having PCOS [13]. It
was suggested that as PCOS is known to be associated
with high circulating endogenous LH levels, and that this
may persists into the luteal phase [24], that potentially
the endogenous LH was not completely suppressed, with
residual LH supporting the function of corpus luteum and
the implanting embryo [25]. In the current study, we did
not observe any difference in outcomes relative to the cause
of infertility, despite only 28% of the patients having PCOS.
An almost similar size study without a control arm dem-
onstrated good reproductive outcomes too after GnRHa
trigger combined with intensive luteal steroid support,
only [17], however, that study did not report live-birth, the
ultimate goal of assisted conception.
The aggressive luteal steroid support protocol used after
GnRHa trigger, was initially suggested by Engmann by
combining intramuscular progesterone and daily E2
supplementation [13]; however, in the Vietnamese unit
luteal phase monitoring of progesterone and E2 is not
routinely performed as the centre covers a large catchment
area and patients are unable to attend for regular blood
follow up. Whether even better outcomes could have been
achieved by close monitoring of the luteal phase and opti-
misation of the steroid profile is unclear, however, luteal
phase serum oestradiol is often low in non-supplemented
and supplemented cycles after GnRHa trigger [4]. Simi-
larly, optimisation of progesterone levels may be essen-
tial as conception cycles (natural and stimulated) have a
higher, tight range of mid-luteal progesterone levels than
observed with just ovulation [26]. Furthermore, successful
IVF pregnancies have a higher mid luteal progesterone
concentrations than unsuccessful cycles [26]. Whether
the route of administration contributed to our improved
outcomes compared to those previously reported for the
vaginal route is unclear [16]. Previous randomized con-
trolled trials regarding route of progesterone administration
have demonstrated equivalence in normal IVF cycles [27],however, whether this also applies to aggressive luteal
support warrants further assessment.
Recently, in the context of GnRHa triggered cycles, it has
been shown that a peak E2 ≥ 4,000 pg/mL in conjunction
with a higher LH on the day of oocyte trigger is associated
with a 44.9% ongoing pregnancy rate as opposed to 33.2%
rate in women with a peak E2 < 4,000 pg/mL [17]. In our
cohort of 363 women who had a similar protocol, these
findings could not be reproduced and indeed the opposite
was found as a peak E2 < 4,000 pg/mL was associated with
a higher pregnancy rate as compared to those patients
whose peak E2 exceeded 4,000 pg/mL. This disparity
between ours and the previous analysis, may reflect the
small number of women with a peak E2 < 4,000 pg/ml or
that rather than peak E2 being critical, the endogenous
LH level on the day of trigger may be important. The
importance of the endogenous LH level around the time
of trigger is strengthened by the recent observation that
use of a dual trigger (GnRHa trigger and a bolus of hCG
1000 IU) for those women with a peak E2 < 4,000 pg/mL
was associated with an improvement in live birth rate from
30.9% to 52.9% with only one case of mild OHSS reported
[28]. Furthermore, patients with an E2 ≥ 4,000 pg/mL in
the study by Kummer et al. had higher endogenous pre
and post-trigger LH levels, which may have contributed to
supporting the luteal phase [17]. That it reflects LH
activity rather than peak E2 would also potentially be
consistent with the lack of association between peak
oestradiol and pregnancy rates in the present study,
however in our population pre-trigger endogenous LH
on the day of the trigger did not differ among those
women having peak E2 ≥ 4,000 pg/mL and those with
peak E2 < 4,000 pg/mL. This indicates that the suggested
threshold of 4,000 pg/mL may not apply to the Asian
population, consistent with previous reports suggesting
that women of Asian origin have higher E2 for a given
number of oocytes as compared to non- Asian women
[29,30]. When the live-birth rates were stratified per peak
E2 quartiles in the subgroup with a peak E2 ≥ 4,000 pg/mL,
no differences were observed, further strengthening
that peak E2 may not play a critical role in obtaining a
live-birth rate after GnRHa trigger and intensive luteal
support.
Importantly, this is the first study, to our knowledge,
confirming that OHSS may still occur in a GnRHa trigger
protocol even if the luteal support package does not
include exogenous hCG. A previous study has suggested
the possibility of this [31], however, the findings of this
study have subsequently been disputed [32]. Albeit that
the risk is very low with only one case of severe OHSS
developing in the 322 fresh embryo transfers, previous
studies assessing similar protocols did not report any
cases of OHSS which may have reflected their limited
power to detect this, given their smaller sample sizes
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with less embryos transferred which may not be clinically
relevant to some countries [17]. In our series, a twin
pregnancy had occurred in the case complicated with
late onset severe OHSS, which exposed the patient to
high concentrations of endogenous hCG, an established
risk factor of late onset OHSS [33]. Furthermore, this
single case of severe OHSS in our study group occurred in
a young patient with excessive follicular response (27 folli-
cles over 12 mm) and a peak E2 of 18,959 pg/ml. In retro-
spect, it can definitely be argued that a fresh embryo
transfer should not have been performed. However, at
present there are no established follicular cut off levels
to cancel fresh embryo transfer with the intensive luteal
steroid package after GnRHa trigger and the arbitrarily
acceptable range of peak E2 resulting from trials in
women from other ethnic backgrounds may not apply
to the Asian population. Moreover, there were cases in
our cohort with higher peak E2 and follicular response
who had a successful embryo transfer and still achieved
a live-birth without developing OHSS. Thus, our data
suggest that the use of a GnRHa trigger combined with
intensive luteal steroid support will minimise the occur-
rence of late onset OHSS, however does not completely
eliminate it.
We acknowledge that the routine transfer of 3 embryos
performed in the centre may have amplified the risk of
OHSS in women already having a high risk of developing
OHSS [34]; however, in Vietnam, the lack of legal regula-
tions regarding the number of embryos transferred and the
high cost of IVF allows this practise which is also further
encouraged by the couples’ desire to have a multiple preg-
nancy during their first attempt. Undoubtedly, the transfer
of three embryos is not advisable, let alone in women with
excessive ovarian response, and the centre is changing its
policy as a further reduction and close to elimination of the
risk of OHSS could be achieved through single embryo
transfer in this group of patients. However, for patients in
whom the possibility of an OHSS condition is medically
unacceptable, the way to proceed is segmentation of the
cycle [35].
Strengths and limitations
Although this study is the largest cohort study showing
promising live-birth outcomes and a low OHSS risk
following fresh embryo transfer after a GnRHa trigger
combined with aggressive luteal steroid support in an
Asian population, there are a number of limitations. The
retrospective character of the study limits the ability to
select patients and match groups for known confounders.
However, both groups had similar baseline characteristics
(e.g. age and BMI), known to affect the chance of preg-
nancy after fertility treatment [36]. We also included
all the patients having excessive follicular response andeither of two protocols within the duration of the study
without applying further selective processes. Our reported
pregnancy rate in this case series is lower than reported in
other studies using the similar GnRHa protocol [13]. This
may reflect the variation in success rates among different
centres, countries and populations, so the use of a control
arm in our study allows us to present comparative results.
In addition, the luteal steroid support in our study was
discontinued 7 weeks after a positive pregnancy test as
opposed to 10 weeks in the study by Engmann et al. [13]
which could have resulted in a higher miscarriage rate
due to profound luteolysis after GnRHa trigger. How-
ever, so far there is no evidence suggesting the optimal
duration of luteal support after GnRHa trigger. More-
over, the most profound luteal insufficiency is evident
within the first 2 weeks after GnRHa triggering i.e.
several weeks [37] before the luteoplacental shift takes
place. Finally, the miscarriage rate reported by other
studies using luteal support for 10 weeks [17] is not lower
(7.9%) than that of the present study (1.6%). Obviously to
draw firm conclusions regarding the optimal duration of
the steroid luteal phase support after GnRHa trigger a
RCT is warranted.
We appreciate that cancellation of fresh transfers within
both arms due to concerns regarding triggering and devel-
opment of OHSS will have reduced the overall ongoing
pregnancy rate per cycle started, however, our analysis
was performed on an intention to treat basis. We are also
aware of the fact that the transfer of three embryos, until
now routinely performed in the centre, has recently been
shown not to improve the chance of live birth [34], but
substantially increase the risk of OHSS [38] and other
adverse perinatal outcomes [34]. Thus, the single OHSS
case presented herein might potentially have been avoided
with a single embryo transfer [38]. This study should not
be considered as an attempt to encourage the routine
transfer of 3 embryos in women with excessive follicular
response by using the GnRHa trigger, but it provides
additional information on the outcomes of the protocol
in a non Caucasian population with different baseline
and socioeconomic characteristics from those presented
in previous studies.
The reasons for the discordance in miscarriage rates are
not clear, and would warrant confirmation in randomised
controlled trials comparing the two approaches. It can be
debated that the discontinuation of the luteal support at
the day of the pregnancy test at the hCG arm may have
contributed to the higher miscarriage rate in this group.
However, the current evidence does not support that
the prolonged continuation of the luteal phase support
improves the pregnancy rates or eliminates the number
of miscarriages [39,40]. Lastly, although segmentation
of the cycle and freezing of all embryos is an appropriate
alternative for other centres, in Vietnam, this was not
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having requested a fresh transfer irrespective of the
associated risk. Although an alternative modified luteal
support strategy of 1.500 IU hCG at oocyte retrieval
[9] was previously suggested, this strategy was not used
due to the clinicians’ concerns regarding potential OHSS
with exposure to even small amounts of exogenous hCG
in these OHSS high risk patients.
Additional trials should ascertain whether the com-
bination of GnRHa trigger and the intensive luteal steroid
support package in the OHSS high-risk patient is associ-
ated with better clinical outcomes than the use of GnRHa
trigger and subsequent frozen embryo transfer.
Conclusions
This large retrospective cohort study confirms that in Asian
women who are undergoing ovarian stimulation and
develop an excessive ovarian response, the use of a GnRHa
trigger combined with intensive luteal steroid support, only,
can provide them with the opportunity to proceed to fresh
embryo transfer with satisfactory live birth rates. However,
there is still a minor chance of late onset severe OHSS
development despite the absence of exogenous HCG
supplementation. RCTs are warranted to provide upper
cut off limits of follicular response which will determine
when fresh embryo transfer with GnRHa trigger should
be avoided.
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